R727-CL-1628 HoFH

The primary objective of this Phase 3 study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.

Learn More

Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.


Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434